Beam Therapeutics
BEAM
209 hedge funds and large institutions have $2.18B invested in Beam Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 85 increasing their positions, 57 reducing their positions, and 38 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 57
1.68% more ownership
Funds ownership: 77.55% → 79.23% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less funds holding
Funds holding: 224 → 209 (-15)
16% less capital invested
Capital invested by funds: $2.6B → $2.18B (-$420M)
34% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 38
56% less call options, than puts
Call options by funds: $8.74M | Put options by funds: $19.7M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$23.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.1M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$10.2M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$8.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.46M |
Top Sellers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$12.4M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.4M |
| 3 |
Two Sigma Investments
New York
|
-$9.48M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$7.53M |
| 5 |
BlackRock
New York
|
-$5.7M |
BEAM Hedge Fund Activity: Q4 2022 in Review
209 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q4 2022, worth a combined $2.18B — down 16% from $2.6B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of BEAM and 25 opened new positions — a net loss of 13 holders — while 57 trimmed existing stakes and 85 added.
The largest buyer was State Street, adding an estimated $23.8M. The largest seller was ARK Investment Management, cutting an estimated $12.4M.
- 209 institutional investors held Beam Therapeutics (BEAM) as of Q4 2022, down from 224 in Q3 2022.
- Funds reported $2.18B of Beam Therapeutics stock for Q4 2022, down 16% quarter-over-quarter.
- 25 funds opened new Beam Therapeutics positions in Q4 2022 and 38 closed out, a net change of -13 holders.
- The largest Beam Therapeutics buyer in Q4 2022 was State Street, an estimated $23.8M added.
- The largest Beam Therapeutics seller in Q4 2022 was ARK Investment Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q4 2022.